Abstract: TH-PO642
Disease Targeting Properties of Voclosporin in Kidney Transplant and Lupus Nephritis Patients
Session Information
- Lupus Nephritis: Clinical, Outcomes, and Therapeutics
October 24, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Zhou, Simon, Aurinia Pharmaceuticals Inc, Edmonton, Alberta, Canada
- Rehaume, Linda M., Aurinia Pharmaceuticals Inc, Edmonton, Alberta, Canada
- Yap, Ernie, Aurinia Pharmaceuticals Inc, Edmonton, Alberta, Canada
- Leher, Henry, Aurinia Pharmaceuticals Inc, Edmonton, Alberta, Canada
- Hodge, Lucy S., Aurinia Pharmaceuticals Inc, Edmonton, Alberta, Canada
- Huizinga, Robert B., Reformation Consulting Services Inc, Victoria, British Columbia, Canada
Background
Voclosporin (VCS), a second generation calcineurin inhibitor, is approved in the United States and Europe for the treatment lupus nephritis (LN) in combination with background immunosuppressive therapy. VCS does not require therapeutic drug monitoring, and is associated with improved glucose, lipid and electrolyte profiles compared to tacrolimus and cyclosporine. VCS demonstrates non-linear selective tissue disposition in animal models, and in renal transplant and LN clinical trials. Pharmacometric modeling was conducted to assess the selective tissue drug disposition relative to systemic drug exposure in patients with renal transplant or LN, comparing with healthy volunteers.
Methods
Individual VCS blood concentration-time measurements were pooled from single and multiple dose ascending studies in healthy volunteers, the Phase IIb PROMISE study in renal transplant patients, and the Phase II AURA-LV and Phase III AURORA 1 studies in LN patients. The VCS blood exposure data were pharmacometrically modelled using a two-compartment model.
Results
In healthy subjects, VCS has comparable central and peripheral volume of distribution (Vc/Vp of 242/272 L/L) and higher elimination than distribution clearance (CL/Q of 43/16 [L/hr]/[L/h]). In transplant patients, VCS has larger peripheral than central volume of distribution (Vc/Vp of 62/2140 L/L), comparable elimination versus distribution clearance (CL/Q of 58/54 [L/hr]/[L/h]) In LN patients, VCS also has larger peripheral than central volume of distribution (Vc/Vp of 34/2120 L/L), slower distribution than elimination clearance (CL/Q of 41/6 [L/hr]/[L/h]).
Conclusion
The larger peripheral volume of distribution indicates selective peripheral tissue uptake of VCS in patients with renal transplant and LN. This is consistent with immunosuppressive activity of VCS in targeted organs relative to blood circulation. The low blood levels of VCS are consistent with the safety profile of VCS compared to other calcineurin inhibitors. Overall, the higher concentration of VCS in affected tissues may account for the efficacy and safety profiles reported in renal transplant and LN patients.
Funding
- Commercial Support – Aurinia Pharmaceuticals Inc.